Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Mr. Meyers will become an officer of the company and member of Gilead's senior leadership team. Mr. Meyers joined Gilead in 1996 as a regional sales director and has been the Senior Vice President of North American Commercial Operations since 2007. In his 20 years at Gilead, Mr. Meyers has been instrumental in building out the company's commercial operations in North America, including leading successful product launches in HIV, oncology, cardiovascular, respiratory and liver diseases. Prior to Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. He received his Bachelor's degree in economics from Boston College. "Jim has demonstrated a remarkable ability to navigate the complexities of commercial operations, ensuring we reach diverse audiences with information about Gilead's medicines and ultimately that we make those medicines accessible to people in need," said Kevin Young CBE, Chief Operating Officer, Gilead Sciences. "I am confident that as Gilead's portfolio of products continues to grow, Jim's leadership and exceptional track record make him ideally suited to lead our global commercial organization." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.